-
Product Insights
Obsessive-Compulsive Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Obsessive-Compulsive Disorder Clinical Trial Market Report Overview Obsessive-compulsive disorder clinical trial market research report provides top line data relating to the clinical trials on obsessive-compulsive disorder. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials. The...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Post-Traumatic Stress Disorder (PTSD) Clinical Trial Report Overview A total of 704 post-traumatic stress disorder (PTSD) clinical trials were conducted as of January 2024. The PTSD clinical trial report provides a comprehensive understanding of the PTSD clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       North...
-
Product Insights
NewPost-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024
Empower your strategies with our Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2024 report and make more profitable business decisions. Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety medications, and cognitive therapy. The Post-Traumatic Stress Disorder (PTSD) drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewSocial Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2024
Empower your strategies with our Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2024 report and make more profitable business decisions. Social anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impairing ability to function in at least some aspects of daily life. These fears can be triggered by perceived or actual scrutiny from others. The Social Anxiety Disorder (SAD/Social Phobia) drugs in...
-
Product Insights
NewPanic Disorders – Drugs In Development, 2024
Empower your strategies with our Panic Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Panic disorder is an anxiety disorder characterized by regular, sudden attacks of fear. Patients with this disorder have feelings of anxiety, stress, and panic regularly and at any time, often for no apparent reason. Symptoms may include a racing heartbeat, feeling faint, sweating, nausea, and chest pain. The Panic Disorders drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewObsessive-Compulsive Disorder – Drugs In Development, 2024
Empower your strategies with our Obsessive-Compulsive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead the patient to perform repetitive behaviors (compulsions). Symptoms include having repeated thoughts or mental images about certain things, such as fears of germs, dirt, intruders, acts of violence, or hurting loved ones; and doing the same rituals over and over, such as washing hands, locking and unlocking doors, counting,...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Market Report Overview There were a total of 345 social anxiety disorder clinical trials conducted as of August 2023. The social anxiety disorder clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as...
-
Sector Analysis
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Overview In the seven major pharmaceutical markets (7MM: France, Germany, Italy, Japan, Spain, UK, and the US), GlobalData epidemiologists estimated more than 1.02 million acute diagnosed prevalent cases for PTSD in 2023. Post-Traumatic Stress Disorder (PTSD) is a mental disorder that can occur after experiencing a traumatic event. Characterized by symptoms typical of anxiety disorders such as irritability, sleep disturbances, disrupted concentration, and increased heart rate, PTSD is distinguished by the patient...
-
Sector Analysis
Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Body Dysmorphic Disorder Clinical Trials Report Overview Body dysmorphic disorder (BDD), also known as dysmorphophobia, is a severe psychiatric condition in which an individual spends a significant amount of time worrying about flaws in their own or another person’s appearance. These flaws are frequently overlooked by others. BDD can affect people of any age, but it is most common in teenagers and young adults. It affects both men and women. The BDD marketed and pipeline drugs market research report includes...